(a)
$$R_4 (CH_2)_n Z$$
(CH₂)_j Z
(CH₂)_n , or
$$(CH_2)_n Z$$

W is $NHC(=X)R_1$, or -Y-het;

X is O, or S; provided that when X is O, B is not the subsection (b)[.]:

Y is NH, O, or S;

Z is $S(=O)(=N-R_5)$;

R₁ is

- (a) H,
- (b) NH_2 ,
- (c) NHC₁₋₄alkyl,
- (d) C₁₋₄alkyl,
- (e) C₂₋₄alkenyl,
- (f) OC₁₋₄alkyl,
- (g) SC₁₋₄alkyl, or
- (h) $(CH_2)_p C_{3-6}$ cycloalkyl;

at each occurrence, alkyl or cycloalkyl in R₁ is optionally substituted with one or more F, Cl or CN;

 R_2 and R_3 are independently H, F, Cl, methyl or ethyl;

R₄ is H, CH₃, or F;

R₅ is

- (c) $C(=O)C_{1-4}alkyl$,
- (d) $C(=O)OC_{1-4}alkyl$,

FORM PTORSP Rev. 5/1999

- (e) $C(=O)NHR_6$, or
- (f) $C(=S)NHR_{6}$;

R₆ is H, C₁₋₄alkyl, or phenyl;

Cont

at each occurrence, alkyl in R₅ and R₆ is optionally substituted with one or more halo, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, NR₇R₇, oxo, or oxime;

R₇ is H, C₁₋₄alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, CF₃, CH3, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=Q)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=Q)R₇, C(=O)NR₇R₇, or NR₇R₇;

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;

p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

m is 0, 1, or 2;

n is 2 or 3; and — in structure iii is either a double bond or a single bond.

2. A compound of claim 1 having the formula IA:

$$\begin{array}{c} R_2 \\ R_3 \end{array} \longrightarrow \begin{array}{c} O \\ N \end{array} \longrightarrow \begin{array}{c} X \\ R_1 \end{array}$$

IA.

32

46. A compound of claim 2 which is

N-($\{(5S)$ -3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, Z-isomer;

N- $({(5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1}\lambda^4-thiopyran-4-v])$ phenyl]-2oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer; N-($\{(5S)-3-[3-fluoro-4-(1-\{[(methylamino)carbonyl]imino\}-1-oxidohexahydro-1\lambda^4$ thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer; N- $({(5S)-3-[3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1<math>\lambda^4$ -thiopyran-4yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer; N- $({(5S)-3-[3-fluoro-4-(1-[[(ethoxycarbonyl)methyl]imino]-1-oxidohexahydro-1\lambda^4$ thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer; N-({(5S)-3-[3-fluoro-4-(1-{[[(4-nitrophenyl)amino]carbonyl]imino}-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Zisomer; N- $({(5S)-3-[3-fluoro-4-[1-[(aminocarbonyl)imino]-1-oxidohexahydro-1<math>\lambda^4$ -thiopyran-4yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer; N- $({(5S)-3-[3-fluoro-4-[1-[[(aminocarbonyl)methyl]imino]-1-oxidohexahydro-<math>1\lambda^4$ thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer; N-[((5S)-3-{3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxido- $1\lambda^4$, 4-thiazinan-4yl)phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanethioamide; N-[((5S)-3-{3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxido- $1\lambda^4$, 4-thiazinan-4yl)phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]cyclopropanecarbothioamide; N- $[((5S)-3-\{3-fluoro-4-[1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1\lambda^4-thiopyran-4$ yllphenyl\-2-oxo-1,3-oxazolidin-5- yl\)methyl\ cyclopropanecarbothioamide, Z-isomer; N-[((5S)-3-{3-fluoro-4-[1-[[(phenylmethoxy)carbonyl]imino]-1-oxidohexahydro- $1\lambda^4$ -

thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide, Z-isomer; or

thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, Z-isomer.

N- $({(5S)-3-[3-fluoro-4-(1-{[(benzylamino)carbonyl]imino}-1-oxidohexahydro-1\lambda^4-$

of 47.

1. A compound of formula II

$$R_2$$

$$R_3$$

$$A-CH_2-W$$

 Π

put i

or a pharmaceutically acceptable salt thereof wherein:

A is a structure ii

BZ

B is

$$R_4$$
 $(CH_2)_p$ Z $(CH_2)_j$

W is NHC(=X) R_1 , or -Y-het;

X is O, or S;

Y is NH, O, or S;

Z is S(=O)(=N-R₅) and the B ring has the following stereochemistry

 R_1 is

- (a) H,
- (b) NH_2 ,
- (c) NHC₁₋₄alkyl,



- (d) C₁₄alkyl,
- (e) C2-4alkenyl,
- OC₁₋₄alkyl,
- SC₁₄alkyl, or (g)
- (h) $(\dot{C}_{H_2})_p C_{3-6}$ cycloalkyl;

at each occurrence, alkyl or cycloalkyl in R1 is optionally substituted with one or more F, Cl or CN;

R₂ and R₃ are independently H, F, Cl, methyl or ethyl;

 R_4 is H, CH₃, or F;

R₅ is

- H, (a)
- C₁₋₄alkyl, (b)
- $C(=O)C_{1-4}alkyl$, (c)
- (d) $C(=O)OC_{1-4}alkyl,$
- (e) $C(=O)NHR_6$, or
- (f) $C(=S)NHR_{6}$

 R_6 is H, C_{1-4} alkyl, or phenyl;

at each occurrence, alkyl in R₅ and R₆ is optionally substituted with one or more halo, CN, NO₂, phenyl, C_{3-6} cycloalkyl, OR_7 , $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $\dot{S}(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, NR_7R_7 , Oxo, or oxime;

R₇ is H, C₁₄alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, CF₃, CH₃, CN, NO₂, phenyl, C_{3-6} cycloalkyl, OR_7 , $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(\stackrel{\triangle}{=}Q)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, or NR_7R_7 ;

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;

p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

B2 Cynt

m is 0, 1, or 2;

and ----- in structure iii is either a double bond or a single bond...

B3

52. The compound of claim 47 wherein R_1 is cyclopropyl.

ľ

65.

A compound of claim 47 which is

N-($\{(5S)^4\}$ -[3-fluoro-4-(1-imino-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide (Z)-isomer;

N-($\{(5S)$ -3-[3-fluoro-4-(1-imino-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide (Z)-isomer;

N-($\{(5S)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl\}$ methyl)propanethioamide (Z)-isomer;

N-($\{(5S)$ -3-[3-fluoro-4-(1-imino-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)cyclopropanethioamide (Z)-isomer;

N-($\{(5S)$ -3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, Z-isomer;

N-($\{(5S)$ -3-[3-fluoro-4-[1-(methylimino)-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-($\{(5S)$ -3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-($\{(5S)$ -3-[3-fluoro-4-[1-(ethylimino)-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-($\{(5S)-3-[3-fluoro-4-[1-[(phenylmethyl)imino]-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl]$ phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N-($\{(5S)-3-[3-fluoro-4-[1-[(3-phenylpropyl)imino]-1-oxidohexahydro-1\lambda^4-thiopyran-4-yl]$ phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

N- $({(5S)-3-[3-fluoro-4-(1-{[(methylamino)carbonyl]imino}-1-oxidohexahydro-1\lambda^2-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomers$

Cont

N-($\{(5S)-3-[3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1<math>\lambda^4$ -thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer; N-($\{(5S)-3-[3-fluoro-4-(1-[[(ethoxycarbonyl)methyl]imino]-1-oxidohexahydro-1<math>\lambda^4$ -thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer; N-($\{(5S)-3-[3-fluoro-4-(1-\{[(4-nitrophenyl)amino]carbonyl]imino\}-1-oxidohexahydro-1<math>\lambda^4$ -thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, Z-isomer;

BY

N-($\{(5S)$ -3-[3-fluoro-4-[1-[(aminocarbonyl)imino]-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl $\}$ methyl)propanethioamide, Z-isomer; N-($\{(5S)$ -3-[3-fluoro-4-[1-[[(aminocarbonyl)methyl]imino]-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl $\}$ methyl)propanethioamide, Z-isomer; N-($\{(5S)$ -3-[3-fluoro-4-[1-[(2-hydroxyethyl)imino]-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl $\}$ methyl)propanethioamide, Z-isomer; N-($\{(5S)$ -3-[3-fluoro-4-[1-(methylimino)-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl $\}$ methyl)cyclopropanecarbothioamide, Z-isomer; N-[((5S)-3-{3-fluoro-4-[1-[(methoxycarbonyl)imino]-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl]phenyl $\}$ -2-oxo-1,3-oxazolidin-5-yl $\}$ methyl $\}$ cyclopropanecarbothioamide, Z-isomer; N-[((5S)-3-{3-fluoro-4-[1-[[(phenylmethoxy)carbonyl]imino]-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl $\}$ phenyl $\}$ -2-oxo-1,3-oxazolidin-5-yl $\}$ methyl $\}$ acetamide, Z-isomer; or N-($\{(5S)$ -3-[3-Fluoro-4-(1-[[(benzylamino)carbonyl]imino}-1-oxidohexahydro- $1\lambda^4$ -thiopyran-4-yl $\}$ phenyl $\}$ -2-oxo-1,3-oxazolidin-5-yl $\}$ methyl $\}$ acetamide, Z-isomer.